This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Feb;28(2):117-9.

doi: 10.1038/nbt0210-117.

The HER2 testing conundrum

Malorye Allison

PMID: 20139941
DOI: 10.1038/nbt0210-117

The HER2 testing conundrum

Malorye Allison. Nat Biotechnol. 2010 Feb.

. 2010 Feb;28(2):117-9.

doi: 10.1038/nbt0210-117.

Author

Malorye Allison

PMID: 20139941
DOI: 10.1038/nbt0210-117

No abstract available

PubMed Disclaimer

Similar articles

Recommendations for HER2 testing in the UK.
Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson B, Mallon E, Lee PB. Ellis IO, et al. J Clin Pathol. 2000 Dec;53(12):890-2. doi: 10.1136/jcp.53.12.890. J Clin Pathol. 2000. PMID: 11265171 Free PMC article.
Assessment of HER2 status in breast cancer: why, when and how?
Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R. Dowsett M, et al. Eur J Cancer. 2000 Jan;36(2):170-6. doi: 10.1016/s0959-8049(99)00264-6. Eur J Cancer. 2000. PMID: 10741274 Review.
Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
Yaziji H, Gown AM. Yaziji H, et al. Hum Pathol. 2004 Feb;35(2):143-6. doi: 10.1016/j.humpath.2004.01.002. Hum Pathol. 2004. PMID: 14991529 No abstract available.
An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A, Allen D, Happerfield L, Johnson N, Provenzano E, Pinder SE, Tee L, Gu M, Kay EW. O'Grady A, et al. Appl Immunohistochem Mol Morphol. 2010 Dec;18(6):489-93. doi: 10.1097/PAI.0b013e3181e3d893. Appl Immunohistochem Mol Morphol. 2010. PMID: 20661132
Testing for HER2 status.
Hanna W. Hanna W. Oncology. 2001;61 Suppl 2:22-30. doi: 10.1159/000055398. Oncology. 2001. PMID: 11694784 Review.

See all similar articles

Cited by

Profile of neratinib and its potential in the treatment of breast cancer.
Feldinger K, Kong A. Feldinger K, et al. Breast Cancer (Dove Med Press). 2015 Jun 9;7:147-62. doi: 10.2147/BCTT.S54414. eCollection 2015. Breast Cancer (Dove Med Press). 2015. PMID: 26089701 Free PMC article. Review.
Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.
Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Tsongalis GJ, Rademaker AW, Patel JD, Benson AB 3rd, Perez EA, Gradishar WJ. Schink JC, et al. J Natl Cancer Inst. 2014 Sep 12;106(10):dju256. doi: 10.1093/jnci/dju256. Print 2014 Oct. J Natl Cancer Inst. 2014. PMID: 25217578 Free PMC article.
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Moelans CB, et al. Patholog Res Int. 2010 Dec 6;2011:674182. doi: 10.4061/2011/674182. Patholog Res Int. 2010. PMID: 21188213 Free PMC article.
The epidermal growth factor receptor conundrum.
Wilken JA, Baron AT, Maihle NJ. Wilken JA, et al. Cancer. 2011 Jun 1;117(11):2358-60. doi: 10.1002/cncr.25805. Epub 2010 Dec 14. Cancer. 2011. PMID: 24048781 Free PMC article. No abstract available.
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Canonici A, et al. Oncotarget. 2013 Oct;4(10):1592-605. doi: 10.18632/oncotarget.1148. Oncotarget. 2013. PMID: 24009064 Free PMC article.

See all "Cited by" articles

References

1. Cancer. 2009 Nov 15;115(22):5166-74 - PubMed
1. Clin Cancer Res. 2009 Oct 15;15(20):6311-3 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal